Two readouts are approaching for Axsome's AXS-05, and Aldeyra is facing a data-heavy 2019.
A top three of early-stage CAR-T presentations from this year’s Ash meeting that you might have missed.
Nanjing Legend reveals continuing strong responses with its anti-BCMA CAR-T therapy in multiple myeloma, but relapses, a death and missing patients cloud the results.
The latest Lentiglobin data impress, but launch worries could clip Bluebird’s wings.
Launch could be trickier than approval, not least because of problems diagnosing patients with primary haemophagocytic lymphohistiocytosis.
Investors had been awaiting an update on voxelotor with trepidation, but a lenient FDA has lit up the company’s Ash.
Amid a frenzy of BCMA-targeting multiple myeloma therapies Bluebird Bio’s bb21217 falls neatly into the Goldilocks zone.
After years in the wilderness acute myeloid leukaemia is seeing a wave of activity, and there could be more targeted agents to come.
Ash presentations suggest that the lead asset Celgene acquired through its $9bn takeover of Juno is undergoing a shift of focus.